Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.31 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416413 | 0.81 | NR4A2 (0.40) | NR4A2BRD4CYP1A2CYP2C19PKM | |
| SCHEMBL22906126 | 0.79 | NR4A2 (0.39) | NR4A2BRD4MAPK14IMPDH2IMPDH1 | |
| SCHEMBL16417169 | 0.78 | ALDH1A1 (0.36) | NR4A2BRD4CYP1A2CYP2C19PKM | |
| SCHEMBL17838262 | 0.78 | ALDH1A1 (0.36) | NR4A2BRD4CYP1A2CYP2C19PKM | |
| SCHEMBL29712831 | 0.76 | MAPT (0.36) | NR4A2POLBHPGDNPSR1 | |
| SCHEMBL17838276 | 0.75 | BAZ2B (0.45) | NR4A2BRD4CYP1A2CYP2C19KDM4E | |
| SCHEMBL28854899 | 0.74 | POLB (0.36) | CYP2C19POLBAPEX1KDM4EBAZ2B | |
| SCHEMBL16416973 | 0.73 | BAZ2B (0.40) | PKMHPGDNPSR1BAZ2BBAZ2A | |
| SCHEMBL16416854 | 0.72 | SMN1; SMN2 (0.33) | KDM4EHPGD | |
| SCHEMBL17838289 | 0.72 | POLB (0.36) | POLBAPEX1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108047115-B | Glyoxylamide-substituted pyrrole amide derivatives and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-06-29 | — | — | CN | disclosed |
| US-10450270-B2 | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-22 | — | — | US | disclosed |
| EP-3357906-A1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2018-08-08 | — | — | EP | disclosed |
| EP-3024819-B1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-21 | — | — | EP | disclosed |
| US-20160176817-A1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-23 | — | — | US | disclosed |
| EP-3024819-A1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2016-06-01 | — | — | EP | disclosed |
| WO-2015011281-A1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2015-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450270-B2 | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | GRHPR, AGXT, GLS2 | NR4A2 2490/4885BRD4 150/4885CYP1A2 404/4885 |
| US-20160176817-A1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | GRHPR, AGXT, GLS2 | NR4A2 2490/4885BRD4 150/4885CYP1A2 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.